Leal Health

Company Overview

Snapshot

Founded in December 2017 by Tzvia Bader, Guy Gildor, and Avital Gaziel, Leal Health operates with 11–50 employees. The company has raised $54.2 million across 6 funding rounds from 8 investors. A significant milestone for the company was its acquisition by Nexus Precision Health in February 2026.

Business overview

Leal Health is an AI-powered decision support platform focused on accelerating access to advanced cancer treatments. The company's core technology provides patients with instant access to precise treatment options, including clinical trials. It also assists pharmaceutical and biotech industries in developing patient-centric clinical trials and gaining real-time analytics on patient barriers and motivations. Leal Health operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Patient Engagement, serving patients, healthcare providers, and pharmaceutical companies.

Strategic signal

Leal Health was acquired by Nexus Precision Health in February 2026. This acquisition signals a strategic move to accelerate precision medicine at scale, integrating Leal Health's AI-powered platform into a broader ecosystem. For investors, this demonstrates a successful exit and validation of Leal Health's technology and market position in the rapidly evolving health tech landscape.

Company Intelligence Q&A

What was the most significant recent corporate development for Leal Health?

Leal Health was acquired by Nexus Precision Health in February 2026. This acquisition is expected to accelerate precision medicine at scale by integrating Leal Health's AI-powered platform.

What was a key technological advancement for Leal Health in 2023?

In December 2023, Leal Health enhanced its cancer-care-focused patient platform by integrating generative AI. This upgrade aims to improve the prediction of patient treatment regimens based on their medical history and current conditions, helping healthcare providers identify and educate potential patients more effectively.

When did Leal Health expand its platform to include FDA-approved cancer treatment decision support?

In June 2023, Leal Health expanded its AI-powered platform to include FDA-approved cancer treatment decision support. This marked the first time patients had a single access point to explore personalized treatment options, including standard care and clinical trials.

Which investors participated in Leal Health's Series A funding round in February 2022?

In February 2022, Leal Health secured a Series A funding round led by.

What was the focus of Leal Health's partnership with YonaLink in September 2021?

In September 2021, Leal Health (then TrialJectory) and YonaLink received a grant from the BIRD Foundation to develop a tool that automates the conduct of clinical trials. This collaboration aimed to reduce costs, time, and resources by screening patients and connecting them to trial sites, shifting the focus of clinical trials from site-oriented to patient-oriented.